MedTrace Logo

Immunogenicity of the ChAdox1 n CoV-19 Vaccine With 12-dose Vial

NCT04961385 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2021-07-14

No results posted yet for this study

Summary

ChAd0x1 nCoV-19 (AZD 1222) is the main vaccine that is planned to roll-out in Thailand and involve vaccinating people especially in high-risk categories. This vaccine is contained in the multiple-dose vial for vaccinating 10 recipients for 0.5 mL each. However, the additional volume of vaccine was overfilled to 6.5 mL per vial which the vaccination can be administered to more than 10 doses. The University Hospital Network (UHOSNET) and Faculty of Medicine Vajira Hospital, Navamindradhiraj University have jointly stipulated the preparation and vaccination of ChAdox1 - n CoV-19 vaccine with 12 doses per vial injection with traditional 21 or 24 G needle. Taken together, The investigators planned to investigate the immune response of participants after first dose of ChAd0x1 nCoV-19 vaccination with such technique

Conditions

  • Covid19
  • Vaccine
  • Immunogenicity

Interventions

BIOLOGICAL

Immunogenicity after first dose of participants who received first dose of ChAdox-1 n COV-19 vaccine

Blood samples were taken from the vaccinated participants for antibody testing against SARS-CoV-2

Sponsors & Collaborators

  • Bangkok Metropolitan Administration Medical College and Vajira Hospital

    lead OTHER_GOV

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-01
Primary Completion
2021-05-31
Completion
2021-05-31

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04961385 on ClinicalTrials.gov